Zhao Qing, Che Xudong, Zhang Hongxia, Tan Guanping, Liu Liu, Jiang Dengzhi, Zhao Jun, Xiang Xiang, Sun Xiaochuan, He Zhaohui
Department of Neurosurgery, the First Affiliated Hospital of Chongqing Medical University, 1 Friendship Road, Chongqing 400016, China.
Int J Mol Sci. 2017 Apr 18;18(4):854. doi: 10.3390/ijms18040854.
Early brain injury (EBI) is considered to be the major factor associated with high morbidity and mortality after subarachnoid haemorrhage (SAH). Apoptosis is the major pathological mechanism of EBI, and its pathogenesis has not been fully clarified. Here, we report that thioredoxin-interacting protein (TXNIP), which is induced by protein kinase RNA-like endoplasmic reticulum (ER) kinase (PERK), participates in EBI by promoting apoptosis. By using adult male Sprague-Dawley rats to establish SAH models, as well as Terminal dexynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL) staining, immunofluorescence, and western blot, we found that TXNIP expression significantly increased after SAH in comparison to the sham group and peaked at 48 h (up to 3.2-fold). Meanwhile, TXNIP was widely expressed in neurons and colocalized with TUNEL-positive cells in the hippocampus and cortex of SAH rats. After administration of TXNIP inhibitor-resveratrol (60 mg/kg), TXNIP small interfering RNA (siRNA) and the PERK inhibitor GSK2656157, TXNIP expression was significantly reduced, accompanied by an attenuation of apoptosis and prognostic indicators, including SAH grade, neurological deficits, brain water content, and blood-brain barrier (BBB) permeability. Collectively, these results suggest that TXNIP may participate in EBI after SAH by mediating apoptosis. The blockage of TXNIP induced by PERK could be a potential therapeutic strategy for SAH treatment.
早期脑损伤(EBI)被认为是蛛网膜下腔出血(SAH)后高发病率和高死亡率的主要相关因素。细胞凋亡是EBI的主要病理机制,其发病机制尚未完全阐明。在此,我们报告由蛋白激酶RNA样内质网(ER)激酶(PERK)诱导的硫氧还蛋白相互作用蛋白(TXNIP)通过促进细胞凋亡参与EBI。通过使用成年雄性Sprague-Dawley大鼠建立SAH模型,以及采用末端脱氧核苷酸转移酶(TdT)介导的dUTP缺口末端标记(TUNEL)染色、免疫荧光和蛋白质印迹法,我们发现与假手术组相比,SAH后TXNIP表达显著增加,并在48小时达到峰值(高达3.2倍)。同时,TXNIP在神经元中广泛表达,并与SAH大鼠海马和皮质中的TUNEL阳性细胞共定位。给予TXNIP抑制剂白藜芦醇(60mg/kg)、TXNIP小干扰RNA(siRNA)和PERK抑制剂GSK2656157后,TXNIP表达显著降低,同时细胞凋亡以及包括SAH分级、神经功能缺损、脑含水量和血脑屏障(BBB)通透性在内的预后指标均有所减轻。总体而言,这些结果表明TXNIP可能通过介导细胞凋亡参与SAH后的EBI。PERK诱导的TXNIP阻断可能是SAH治疗的一种潜在策略。